Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD22 Positive”

38 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 38 results

Early research (Phase 1)Active Not RecruitingNCT03233854
What this trial is testing

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+1 more
Stanford University 56
Testing effectiveness (Phase 2)Ended earlyNCT03094611
What this trial is testing

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

Who this might be right for
CD22 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Study completedNCT03289455
What this trial is testing

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
B Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic Leukemia+1 more
Autolus Limited 23
Early research (Phase 1)Study completedNCT01925131
What this trial is testing

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Acute Leukemias of Ambiguous LineageB-cell Adult Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia+2 more
SWOG Cancer Research Network 50
Testing effectiveness (Phase 2)WithdrawnNCT03851081
What this trial is testing

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Allogeneic Hematopoietic Stem Cell Transplantation RecipientBlasts 5 Percent or More of Bone Marrow Nucleated CellsBlasts 5 Percent or More of Peripheral Blood White Cells+5 more
Roswell Park Cancer Institute
Early research (Phase 1)UnknownNCT04204161
What this trial is testing

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia, ChildhoodRefractory B-cell Acute Lymphoblastic Leukemia, ChildhoodRelapsed/Refractory B-cell Lymphoma, Childhood
Shenzhen BinDeBio Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT04788472
What this trial is testing

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

Who this might be right for
B-Cell Acute Lymphoblastic Leukemia, Adult
Zhejiang University 28
Testing effectiveness (Phase 2)Study completedNCT01664910
What this trial is testing

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Who this might be right for
Hematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center 27
Early research (Phase 1)Looking for participantsNCT06752785
What this trial is testing

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

Who this might be right for
Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center 10
Early research (Phase 1)Study completedNCT00001271
What this trial is testing

A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma

Who this might be right for
B Cell Lymphoma
National Cancer Institute (NCI) 24
Early research (Phase 1)Study completedNCT01535989
What this trial is testing

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

Who this might be right for
B-cell Lymphoma Refractory
Cristiana Sessa 25
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Large-scale testing (Phase 3)Study completedNCT01564784
What this trial is testing

Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoblastic Leukemia
Pfizer 326
Testing effectiveness (Phase 2)Looking for participantsNCT06213636
What this trial is testing

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).

Who this might be right for
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukemia, in RelapseNon-Hodgkin Lymphoma, B-cell+4 more
Essen Biotech 75
Testing effectiveness (Phase 2)Study completedNCT00867087
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma, B-Cell
Pfizer 64
Testing effectiveness (Phase 2)WithdrawnNCT04029038
What this trial is testing

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Who this might be right for
CD19 PositiveCD22 PositiveMinimal Residual Disease+7 more
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT02577094
What this trial is testing

Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia

Who this might be right for
Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Nantes University Hospital
Testing effectiveness (Phase 2)Study completedNCT00098839
What this trial is testing

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Recurrent Childhood Acute Lymphoblastic Leukemia
Children's Oncology Group 134
Early research (Phase 1)UnknownNCT05523661
What this trial is testing

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

Who this might be right for
Ph Positive ALLCAR-T CellDasatinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT02981628
What this trial is testing

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic LymphomaRefractory B Acute Lymphoblastic Leukemia+1 more
Children's Oncology Group 80
Next Page